Скачать с ютуб MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors в хорошем качестве

MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors

Ben Tran, MBBS, FRACP, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia, discusses the development of a novel anti-CTLA-4 therapy. High doses of anti-CTLA-4 therapy improve overall survival by increasing T-cell proliferation and activation. However, high doses of anti-CTLA-4 therapy also have substantial side effects. MEDI5752 is a novel agent that could overcome the toxicity that limits the delivery of these higher doses. MEDI5752 is a monovalent bispecific antibody that targets both PD-1 and CTLA-4. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.